PMI's U.S. Arrival Makes Us Wonder Where Will BAT's Next Move Land?

BAT by Charlotte Yu, edited by Sophia
Apr.08.2024
PMI's U.S. Arrival Makes Us Wonder Where Will BAT's Next Move Land?
As its longstanding rival prepares to enter the U.S. market, British American Tobacco (BAT) is expected to make strategic moves in response. 2FIRSTS has been closely monitoring the capital market and the company's latest developments to uncover potential actions BAT may take.

In March 2024, during an interview with the Financial Times, Tadeu Marroco, the CEO of British American Tobacco (BAT), dismissed the idea of moving the company's listing from London to New York, calling it "a distraction." This comes after the top ten shareholders who had been pushing for this change have exited their holdings in the tobacco company.

 

Marroco told the Financial Times that changing the listing location "would create a lot of internal disruption," and he did not see the benefits outweighing these negative impacts. He added that there were "many other things" he needed to focus on, including revenue in the United States and new products.

 

His specific mention of the U.S. market led some industry observers to the trial launch of PMI's HNB product IQOS in the country this year. With the arrival of its old rival imminent, what moves will BAT make in the United States? 2FIRSTS has followed up on the capital market and the company's latest dynamics to find any clues.

 

Capital Market: Continuously Valued by Institutional Investors

 

Over the past year, BAT's (LON.BATS) share price has fallen by about 21%, from 2,872.00 GBX (pence) on March 19, 2023, to 2,376.00 GBX on March 19, 2024. However, so far, the top 15 shareholders of BAT still hold 50% of the company's shares, and there have been significant purchases by insiders since March.

 

From publicly disclosed information, hedge funds do not hold much of BAT's shares. Capital Research and Management Company is the largest shareholder, holding 14% of the issued shares. The second-largest shareholder holds about 10% of the circulating shares, while the third-largest holds 8.6%. The large holdings of BAT's shares by these institutions mean they have a significant influence on the company's share price, and such institutional capital investment in the company is usually a huge vote of confidence in its future. Even though the share price has fallen over the past year, its future performance is still widely favored by institutions.

 

菲莫登陆美国在即:资本市场上的英美烟草的下一步棋将落在何方
BAT's shareholders | BAT

 

Relationship with PMI in NGP Field: Thawing the Ice or Continuing the Struggle?

 

The big news in the tobacco industry at the start of 2024 was undoubtedly the patent settlement between PMI and BAT in the heated tobacco field. On February 2, Eastern Time in the United States, both companies announced on their official websites that they had resolved intellectual property disputes related to heated tobacco and electronic cigarette products.

 

BAT is facing the challenge of reversing the decline in cigarette sales in its largest market, the United States. The company's spokesperson stated that this was mainly due to consumers switching to cheaper brands and new types of tobacco. However, BAT has always been lagging behind PMI in the new tobacco market, the latter having achieved great success with its heated tobacco product IQOS.

 

At the same time, Marroco admitted to the media that BAT "started late" in the field of heated tobacco products. This was the first time BAT had "shown weakness" in public. However, he stated that due to the company's market share base in the United States, the company has the capability to catch up in the future. "We have a huge business in the U.S. that can be used to sell (new tobacco products)."

 

BAT's goal is for revenue from alternative products (such as Vuse vapor e-cigarettes and Glo heated tobacco devices) to reach half of total revenue by 2035, eleven years from now. But in 2023, this figure was still at 16%. With PMI resolving patent issues and landing in the United States, if BAT wants to achieve its goal in the next ten years, it must compete head-to-head with PMI in the U.S. market.

 

Increased investment in development shows BAT's determination to "fight to the end" with PMI in the new tobacco field. In March 2023, BAT opened an innovation center at its global R&D headquarters in Southampton, which will play a key role in the company's continued transformation and vision of a "better future." The facility, costing £30 million, provides nine specially designed technical spaces focused on developing nicotine pouches, vapor e-cigarettes, and more. Prior to this, in 2021, BAT had already opened innovation centers in Trieste, Italy, and Shenzhen, China, and invests £300 million annually in R&D for new category products.

 

According to financial reports, BAT spent about £408 million on R&D in 2023, a 26% increase from the £323 million in 2022, mainly invested in harm reduction products. BAT's financial report screenshot | Source: BAT

 

菲莫登陆美国在即:资本市场上的英美烟草的下一步棋将落在何方
BAT financial report|BAT

 

"Cutting Flesh" in Russia, Reducing Holdings in ITC: Capital Retreat and Diversified Investment

 

BAT recently sold shares in ITC worth about 17 billion Indian rupees. Before the sale, BAT held about 29% of the shares in ITC, making it the largest shareholder. BAT had two representatives on the ITC board and was often the only shareholder to raise opinions and questions about the company's operations.

 

CEO Marroco told analysts that because BAT "does not need to hold more than 25% of the shares in ITC to have strategic influence and veto power," the consideration for divestment was mainly based on "cost-effectiveness."

 

However, over the past year, BAT has also stumbled in selling and divesting. In September 2023, BAT, which had been looking to exit the Russian market, finally sold its assets to a consortium led by a local Russian management team, ending a transaction process that lasted for 18 months. However, in a later update on December 6, Marroco stated that BAT had suffered significant losses in the sale of its Russian and Belarusian assets, and that the proceeds BAT received accounted for only a small part of the true value of its businesses in Russia and Belarus.

 

2FIRSTS inquired with BAT's public relations staff in Singapore whether there were any more public divestment plans, but had not received a response by the time of publication. The losses from the sale of Russian and Belarusian businesses can be expected to make British American Tobacco act more cautiously in the following period.

 

In contrast to the contraction trend in tobacco business, BAT's investment arm, Btomorrow Ventures (BTV), is exploring more investment areas. Since its establishment in 2020, BTV has completed 25 investments, with funds mainly flowing to consumer-led innovative technology and sustainable development fields.

 

In addition, in 2023, BAT's subsidiary The Water Street Collective Ltd piloted a series of its own functional beverage brands Ryde in the Australian and Canadian markets; it also signed a joint venture agreement with Charlotte's Web through a subsidiary. 

 

菲莫登陆美国在即:资本市场上的英美烟草的下一步棋将落在何方
Functional beverage Ryde product page screenshot

 

Whether BAT will gradually reduce its reliance on the tobacco sector in the capital market through diversified investments is worth watching.

 

2FIRSTS will continue to follow BAT's movements in the capital market and the market share of new types of products.

Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia’s Vape Device Labeling Regime Enters Force: Registration Starts in September, Mandatory Coding in December
Russia's digital labeling regime for reusable e-cigarettes and similar personal vaping devices entered its first mandatory phase in September 2026. From September 1, manufacturers, importers and other market participants must register with the national Chestny ZNAK tracking system. From December 1, newly manufactured and imported covered devices will be required to carry digital identification codes and be reported as entering circulation. Russia has also issued new operational guidance for imports, marking the transition from a voluntary pilot to phased mandatory implementation.
Sep.15
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
Huabao’s H1 2026 results show the company advancing across three connected fronts: international expansion, entry into next-generation tobacco supply chains and diversification beyond its traditional tobacco-related base. Overseas revenue rose 216.08% to CNY 96.02 million, while non-flavor businesses reached 42.2% of total revenue. Huabao also said it had entered the supply chains of leading global tobacco customers, as its nutrition, food ingredient, fragrance and personal-care businesses gained ground in Europe, Southeast Asia, Australia and New Zealand. However, adjusted net profit increased only 2.78%, and next-generation tobacco revenue was not separately disclosed, showing that the transformation is reshaping revenue and customer exposure but has yet to translate fully into underlying earnings.
Aug.28
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Asia Manufacturing Corp. has invested ₱2.1 billion, or about $37 million, in its manufacturing site in Malvar, Batangas, Philippines, to expand tobacco-processing capabilities. About ₱1.9 billion is allocated to JTI's first Dry Ice Expanded Tobacco, or DIET, facility in Southeast Asia, while more than ₱177 million has been spent on expanding its Controlled Atmosphere treatment facility. The Batangas plant supplies the Philippine market and exports to 22 overseas markets, making it one of JTI's key manufacturing hubs in Asia.
Sep.24
China’s Jinhua Tobacco Launches CNY 2.7 Million Procurement for E-Cigarette Violation Lead Monitoring Services
China’s Jinhua Tobacco Launches CNY 2.7 Million Procurement for E-Cigarette Violation Lead Monitoring Services
Jinhua Tobacco, a municipal tobacco company in China’s Zhejiang province, has launched a public tender for e-cigarette-related violation lead monitoring and consulting services. The project is valued at CNY 2.7 million and covers data resource integration and analytical consulting services for 36 months from contract signing. The procurement reflects the use of external data and analysis services to support local tobacco companies’ market oversight activities related to e-cigarettes.
Aug.07
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29